Breast Cancer Clinical Trials in Bordeaux
13 recruitingBordeaux, France
Showing 1–13 of 13 trials
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 1Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company720 enrolled67 locationsNCT05768139
Recruiting
Not Applicable
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Breast Cancer
Institut Claudius Regaud120 enrolled25 locationsNCT05378204
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Not Applicable
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast CancerLung CancerComorbidities and Coexisting Conditions
Institut Bergonié720 enrolled10 locationsNCT05720910
Recruiting
Phase 1Phase 2
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Breast Cancer
Novartis Pharmaceuticals58 enrolled32 locationsNCT06247995
Recruiting
Not Applicable
Circulating Tumor DNA After Neoadjuvant Chemotherapy
Breast Cancer
Institut Bergonié180 enrolled1 locationNCT03357120
Recruiting
Bergonie Institute Breast Cancer Database
Breast Cancer
Institut Bergonié30,000 enrolled1 locationNCT02893761
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Not Applicable
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer
Breast CancerCognitive Dysfunction
Centre Francois Baclesse300 enrolled25 locationsNCT06027632
Recruiting
Phase 1
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Breast Cancer
Novartis Pharmaceuticals48 enrolled25 locationsNCT05870579
Recruiting
Not Applicable
Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Postoperative Radiotherapy for Breast Cancer
Breast CancerFibrosis
Association Francaise pour la Recherche Thermale110 enrolled10 locationsNCT05874492
Recruiting
FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
Breast Cancer
Centre Hospitalier Universitaire de Besancon4,500 enrolled5 locationsNCT06185569